Company profile: SomaLogic
1.1 - Company Overview
Company description
- Provider of protein biomarker discovery and clinical diagnostics solutions, offering SOMAmers (Slow-Offrate Modified Aptamers) and the SomaScan Assay, including the 11K Assay v5.0 for profiling 11,000 proteins per sample. Services include customizable SomaScan Panels, SomaSignal clinical tests, and fee-for-service SomaScan Assay delivery via a CLIA-certified, CAP-accredited lab and a worldwide network of authorized sites.
Products and services
- SomaScan 11K Assay v5.0: The latest multiplexed assay profiles 11,000 proteins per sample using SOMAmer reagents, delivering comprehensive biological insights for biomarker discovery and clinical diagnostics from minimal sample volumes
- SomaScan Assay: A high-throughput assay quantifies thousands of proteins from a small sample volume for protein detection, biomarker discovery, and clinical diagnostics, leveraging SOMAmer-based binding for precise, specific measurements
- SomaSignal Tests: Clinical tests employ pre-analytical variation assessment to ensure data accuracy, enabling monitoring of clinical metrics associated with diseases like cardiovascular disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SomaLogic
Afyren
HQ: France
Website
- Description: Provider of biotechnological and green chemistry solutions that valorize non-food biomass into biosourced molecules and natural organic acids. Offers AFYREN NEOXY production facility, FLAVYREN flavor and fragrance acids with a low carbon footprint, and a circular eco approach using organic waste and aiming for zero industrial waste via by-product valorization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Afyren company profile →
BioSeek
HQ: United States
Website
- Description: Provider of cell-based human disease models for drug discovery and development, offering BioMap Systems—human primary cell-based assay systems for indications in vascular inflammation, cardiovascular and respiratory diseases, and fibrosis—and programs for the discovery of lead compounds.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioSeek company profile →
SynAgile
HQ: United States
Website
- Description: Provider of DopaFuse, a continuous oral infusion therapy designed to stabilize L-DOPA levels for Parkinson’s disease patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SynAgile company profile →
Inscripta
HQ: United States
Website
- Description: Provider of digital genome engineering solutions for life sciences.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inscripta company profile →
Expedeon
HQ: United States
Website
- Description: Provider of cutting-edge innovative reagents and services for life sciences and diagnostics, with applications across workflows including protein electrophoresis, liquid biopsy, whole genome amplification, antibody- and protein-labeling, and immunoassay development; offering off-the-shelf products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Expedeon company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SomaLogic
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SomaLogic
2.2 - Growth funds investing in similar companies to SomaLogic
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SomaLogic
4.2 - Public trading comparable groups for SomaLogic
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →